We are live on ! Find out more
PRVB

Provention Bio

Delisted

PRVB was delisted on the 26th of April, 2023.

115 hedge funds and large institutions have $100M invested in Provention Bio in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more call options, than puts

Call options by funds: $3.16M | Put options by funds: $842K

46% more capital inflows, than outflows

Capital inflows: $11.6M | Capital outflows: $7.96M

26% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 19

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

2% more funds holding

Funds holding: 113 → 115 (+2)

0.87% more ownership

Funds ownership: 38.14% → 39.01% (+0.87%)

Holders
115
Holders Change
+2
Holders Change %
+1.77%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
32
Reduced
28
Closed
19
Calls
$3.16​M
Puts
$842​K
Net Calls
+$2.32​M
Net Calls Change
-⁠$4.07​M

PRVB Hedge Fund Activity: Q2 2022 in Review

115 of the 5,965 institutional investors tracked by Wall St. Rank reported a position in Provention Bio (PRVB) for Q2 2022, worth a combined $100M — down 44% from $177M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PRVB positions and 19 closed out — a net gain of 5 holders — while 32 added to existing stakes and 28 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $2.81M. The largest seller was Perceptive Advisors, cutting an estimated $3.23M.

  • 115 institutional investors held Provention Bio (PRVB) as of Q2 2022, up from 113 in Q1 2022.
  • Funds reported $100M of Provention Bio stock for Q2 2022, down 44% quarter-over-quarter.
  • 24 funds opened new Provention Bio positions in Q2 2022 and 19 closed out, a net change of +5 holders.
  • The largest Provention Bio buyer in Q2 2022 was MPM BioImpact, an estimated $2.81M added.
  • The largest Provention Bio seller in Q2 2022 was Perceptive Advisors, an estimated $3.23M sold.

Based on aggregated 13F filings for Q2 2022.